|1.||Mackay, Lynette B: 2 articles (02/2008 - 06/2006)|
|2.||Garfield, Robert E: 2 articles (02/2008 - 06/2006)|
|3.||Gilles, Erard: 1 article (07/2015)|
|4.||Proniuk, Stefan: 1 article (07/2015)|
|5.||Bexon, Alice: 1 article (07/2015)|
|6.||Ramos, Haydeé L: 1 article (07/2015)|
|7.||Zukiwski, Alexander: 1 article (07/2015)|
|8.||Denot, Caroline: 1 article (07/2015)|
|9.||Chassard, Didier: 1 article (07/2015)|
|10.||Lokiec, François: 1 article (07/2015)|
|1.||Breast Neoplasms (Breast Cancer)
02/01/1999 - "In conclusion Onapristone can induce tumour responses in human breast cancer."
02/01/1999 - "19 patients either with locally advanced breast cancer (n = 12) or who were elderly, unfit patients with primary breast cancer (n = 7) received Onapristone 100 mg/day. "
08/01/1998 - "Influence of treatment with onapristone on the IGF-system in breast cancer patients."
07/01/2015 - "Onapristone is an antiprogestin with activity in breast cancer and is under investigation for use in endometrial, ovarian and prostate cancers. "
01/22/2015 - "Further, combination treatment of breast cancer cells with both onapristone and IGF1R tyrosine kinase inhibitor AEW541 was more effective than either agent alone. "
|2.||Premature Obstetric Labor (Premature Labor)
02/01/2008 - "Controls (group 1: n = 4) and preterm labor models (group 2: n = 4, treated with onapristone) were used. "
04/01/1998 - "(4) The characteristics of onapristone-induced preterm labor are generally similar to those of spontaneous term labor. "
09/01/1997 - "Preterm labor was induced with the administration of a single injection of the antiprogestin onapristone (10 mg). "
07/01/1996 - "On day 17 of gestation groups of animals were injected subcutaneously with a single dose of either 3 or 30 mg/kg onapristone; animals were monitored for preterm labor and delivery for up to 48 hours. "
04/01/1998 - "Electrical activity during pregnancy (nonlabor, days 18 to 22), term labor (day 22), and preterm labor (onapristone injected on day 18, delivery on day 19) was measured with use of electrodes attached to the uterine wall and to the abdominal surface. "
12/01/1995 - "A 40 and 50% remission of endometriosis was observed at each location after the administration of 2.0 mg onapristone, whereas 50 and 63% (location A) and 50 and 75% (location B) remissions were found after the administration of 0.4 and 2.0 mg of ZK 136 799 respectively. "
12/01/1995 - "These findings may be a further indication of the future potential of antiprogestins such as onapristone and ZK 136 799 in the treatment of endometriosis."
12/01/1995 - "ZK 136 799 was also more potent than onapristone in growth inhibition (85 versus 48% for location B) in animals with persistent endometriosis. "
12/01/1995 - "The effects of the progesterone antagonists (antiprogestins) onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis were studied in intact female rats. "
12/01/1995 - "Effects of the progesterone antagonists onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis in intact rats."
09/01/2009 - "A comparable antitumor effect of onapristone (ON) on rat Dunning tumors was found in our laboratories. "
03/01/1992 - "It was established by morphometric procedures that treatment with Onapristone triggers differentiation of the mitotically active polygonal tumor epithelial cell towards secretory active glandular structures and acini. "
04/01/1989 - "Treatment of established MXT(+) tumors with ZK 98.299 (1, 10 and 50 mg/mg) resulted in a strong, dose-dependent inhibition of tumor growth. "
01/01/1989 - "Onapristone dramatically blocked tumor growth (% T/C = 7) at the lower dose of MPA; no inhibition (% T/C = 203), however, was detected at the higher dose of MPA. "
05/01/1990 - "Treatment of established MXT(+) tumors by ZK 112.993 at doses of 0.5, 1.0 and 2.0 mg/kg led to a strong inhibition that equalled that of ovariectomy and surpassed that of Onapristone in the lower doses. "
03/01/1994 - "In the in vitro arm of the study, mifepristone and onapristone exhibited cytostatic and cytocidal effects against cultured meningioma cells, regardless of the presence or absence of PR's; however, three PR-negative meningiomas showed no response to any dose of mifeprestone and/or onapristone. "
03/01/1994 - "The present study examined the antitumor effects of mifepristone and a new potent antiprogesterone agent, onapristone; a correlation between the antitumor effects of these antiprogesterones and the presence of PR's in meningiomas in vitro and in vivo was also investigated. "
11/01/1997 - "Growth of meningioma spheroids was quantified in the presence of progesterone and the specific antagonist onapristone. "
03/01/1994 - "These findings suggest that mifepristone and onapristone have an antitumor effect against meningioma cells via the PR's and/or another receptor, such as the glucocorticoid receptor."
|1.||NG-Nitroarginine Methyl Ester (L-NAME)
|2.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|3.||Nitric Oxide (Nitrogen Monoxide)
|4.||Mifepristone (RU 486)
|7.||Estrogen Receptor Modulators (Antiestrogen)
|3.||Heterologous Transplantation (Xenotransplantation)